At­las ramps up a new biotech play­er fo­cused on neu­rol­o­gy, with a $30M round to fund the work

About 6 months ago, Jef­frey Mil­brandt and Aaron DiAnto­nio out of Wash­ing­ton Uni­ver­si­ty pub­lished a high-pro­file pa­per in Neu­ron high­light­ing the role that SARM1 played …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER